Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.

Proceedings of the Japan Academy. Series B, Physical and biological sciences - 1 Jan 2020

Inoue Akira

Abstract excerpt

The identification of mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC). The effectiveness of individualized treatment using EGFR tyrosine kinase inhibitors (TKIs) for EGFR-mutated NSCLC has mainly been clarified in clinical trials within Japan, and EGFR-TKI monotherapy has been established as the standard first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32788550
DOI: 10.2183/pjab.96.020
PMCID: PMC7443375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.PMID 32788550Read ↗

[More Personalized Treatment using Diversified Molecular Targeted Therapy Strategies for EGFR Mutation-Positive Non-Small-Cell Lung Cancer-Sequential Treatment Comprising First- and Second-Line Therapy with EGFR-TKIs and Treatment Options in Combination with Anti-Angiogenic Agents].Semantic proximity Read ↗

[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor].Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC).Semantic proximity Read ↗

[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].Semantic proximity Read ↗

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?Semantic proximity Read ↗

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.Semantic proximity Read ↗

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.Semantic proximity Read ↗

[Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer].Semantic proximity Read ↗

Personalized medicine for non-small-cell lung cancer.Semantic proximity Read ↗

First- Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup AnalysisSemantic proximity Read ↗

[Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.